|
½Ã¹ÍÄÚ¸®¾Æ |
[½Ã¹ÍÄÚ¸®¾Æ] Medical Writing Leader ä¿ë
¼¿ï °³²±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
09.10 |
|
|
PSI CRO Korea |
[PSI CRO Korea] CTA I/II, Sr.CTA
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CTA/CRC |
1³â¡è |
ä¿ë½Ã |
02.08 |
|
|
½Ã¹ÍÄÚ¸®¾Æ |
[½Ã¹ÍÄÚ¸®¾Æ] CRA(I, II, Sr.) ä¿ë
¼¿ï °³²±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
09.10 |
|
|
¶ó¿ÂÄ¿¸Ó½º ÁÖ½Äȸ»ç |
ETC/OTC ÀǾàÇ° ¹× °Ç±â½Ä ¿µ¾÷/ ¸¶ÄÉÆÃ
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
10.24 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Feasibility - Site ID Specialist
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
SSU |
2³â¡è |
ä¿ë½Ã |
06.03 |
|
|
´º¸ÞÀ̽º |
[Ã¥ÀÓ±Þ] ¹ÙÀÌ¿À ÀǾàÇ° ¿¬±¸ °³¹ß GMP °øÁ¤°ü¸® ¿¬±¸¿ø
¼¿ï ¼´ë¹®±¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
06.01 |
|
|
ÁÖ½Äȸ»ç ÀνºÆÃÅͽº |
ÀǾàÇ°RA ä¿ë(½ÅÀÔ°¡´É/Á¤±ÔÁ÷)
¼¿ï ¼ºµ¿±¸ | Çз¹«°ü |
°³¹ß/RA/´ë°ü |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.30 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] BD Assistant ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
°æ·Â¹«°ü |
ä¿ë½Ã |
05.27 |
|
|
¾¾¿£¾Ë¸®¼Ä¡ |
[¾¾¿£¾Ë¸®¼Ä¡] ¿µ¹® µ¥ÀÌÅÍ ÀÔ·Â »ç¹«º¸Á¶ Part Timert ä
¼¿ï °³²±¸ | Çз¹«°ü |
»ç¹«/Ãѹ«/¹ý¹«/ƯÇã |
°æ·Â¹«°ü |
ä¿ë½Ã |
05.14 |
|
|
µð¸ó½º |
ÀçÅÃ-Àú³á/½É¾ß ȨÇÇ°ü¸®,´Ü¼øPCÀÚ·áÀÔ·Â(Ãʺ¸°¡´É)
Àü±¹ ÀüÁö¿ª | Çз¹«°ü |
±¤°í/È«º¸/PR/»çº¸ |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
06.24 |
|
|
(ÁÖ)ÈÞ¸Õ¸ÞµðÄ® |
¿£Áö´Ï¾î/ÀÇ·áÀåºñ/·¹ÀÌÁ®Àåºñ/AS/
¼¿ï ¼ºµ¿±¸ | ´ëÇÐ(2~3³â) ÀçÇÐ |
AS/Á¤ºñ/¼ö¸®/¼³Ä¡ |
°æ·Â¹«°ü |
ä¿ë½Ã |
04.07 |
|
|
(ÁÖ)¾¾¿£¾Ë¸®¼Ä¡ |
¾¾¿£¾Ë¸®¼Ä¡ [½ÅÀÔ/°æ·Â] ÀÓ»ó µ¥ÀÌÅÍ °ü¸®ÀÚ (DMA) ¸ðÁý
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
STAT/DM |
°æ·Â¹«°ü |
ä¿ë½Ã |
09.20 |
|
|
PharmaNet |
[Global CRO PharmaNet] °æ·Â CRA ±¸ÀÎ
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
03.30 |
|
|
(ÁÖ)Å´½ºÁ¦¾à |
Å´½ºÁ¦¾à µô·¯ ¹× ÇÁ¸®·£¼ ¸ðÁýÇÕ´Ï´Ù
Àü±¹ ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
»ó½Ãä¿ë |
01.02 |
|
|
(ÁÖ)ÇÑ¿ï¹ÙÀÌ¿À |
(ÁÖ)ÇÑ¿ï¹ÙÀÌ¿À ¿µ¾÷ºÎ Á¤±ÔÁ÷ ä¿ë _ ü¿ÜÁø´ÜÀÇ·á±â±â(´ë
¼¿ï ÀüÁö¿ª, °æ±â ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
ä¿ë½Ã |
08.30 |
|